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ABSTRACT
Burkitt lymphoma (BL) is an aggressive neoplasm characterized by consistent 
morphology and phenotype, typical clinical behavior and distinctive molecular profile. 
The latter is mostly driven by the MYC over-expression associated with the characteristic 
translocation (8;14) (q24; q32) or with variant lesions. Additional genetic events 
can contribute to Burkitt Lymphoma pathobiology and retain clinical significance. 
A pathogenetic role for Epstein-Barr virus infection in Burkitt lymphomagenesis has 
been suggested; however, the exact function of the virus is largely unknown.
In this study, we investigated the molecular profiles (genes and microRNAs) of 
Epstein-Barr virus-positive and -negative BL, to identify specific patterns relying on 
the differential expression and role of Epstein-Barr virus-encoded microRNAs.
First, we found significant differences in the expression of viral microRNAs 
and in selected target genes. Among others, we identified LIN28B, CGNL1, GCET2, 
MRAS, PLCD4, SEL1L, SXX1, and the tyrosine kinases encoding STK10/STK33, 
all provided with potential pathogenetic significance. GCET2, also validated by 
immunohistochemistry, appeared to be a useful marker for distinguishing EBV-
positive and EBV-negative cases. Further, we provided solid evidences that the EBV-
encoded microRNAs (e.g. BART6) significantly mold the transcriptional landscape of 
Burkitt Lymphoma clones.
In conclusion, our data indicated significant differences in the transcriptional 




Burkitt Lymphoma (BL) is an aggressive neoplasm 
characterized by consistent morphology and phenotype, 
typical clinical behavior and distinctive molecular profile. 
The latter is basically determined by MYC over-expression, 
as a consequence of the characteristic translocation (8;14) 
(q24; q32) or of variant genetic aberrancies. Besides MYC, 
additional genetic lesions can be found, with possible 
impact on significance [1–4]. Interestingly, despite BL 
gene expression profile (GEP) is relatively homogeneous 
and distinct from those of other lymphomas, significant 
differences have been recorded among the three classical 
variants, including endemic BL (eBL), sporadic BL (sBL) 
and immunodeficiency-associated BL (ID-BL) [5]. This 
finding was also confirmed by microRNA (miRNA) 
profiling which showed that the three BL variants 
represent the same biological entity but with marginal 
differences between endemic and sporadic BL [6].
Of note, the three BL subtypes differ concerning 
the association with pathogens; in fact, eBL is strictly 
associated with EBV infection as well as with the exposure 
to chronic malaria and arbovirus [5, 7, 8]. Conversely, 
EBV is rarely seen in sBL [5, 7, 8]. EBV has been shown 
to affect the host cell homeostasis at different levels largely 
depending on the latent infection type (i.e. latency type). 
There are three major types of EBV latency that depend on 
different EBV gene expression patterns and are specific for 
different cell/disease types. EBNA1 and EBER antigens 
are expressed in all types of EBV latency, while other 
latent proteins differ among the diverse latency forms [9]. 
Latency I configures an escamotage for effective EBV 
immune escape - as the only protein associated with this 
type of latency, EBNA1, inhibits presentation by MHC-I. 
Differently, latency type II, which is characterized by 
the expression of LMP1 and 2, occurs in patients with 
Hodgkin’s lymphomas and T/NK lymphomas, while 
latency-III, which encompasses expression of all the main 
EBV proteins are expressed, including EBNA1–2-3, 
and LMP1–2, is associated with immunodeficiency/
immunosuppression states like HIV infection or organ 
transplantation, or with in vitro culturing of latency I cells, 
like some BL cell lines [10]. Recently, the contribution 
of different EBV-encoded molecules has been explored 
in BL and post transplant lymphoproliferative disease 
[11]. The influence of EBV on host cell transcriptional 
programs is not only related with the synthesis of latency-
related proteins, rather it is also due to EBV interference 
with host cell miRNA biogenesis and to the synthesis of 
virus-encoded miRNAs [12]. The EBV genome encodes 
for 45 mature miRNAs from 25 precursors, which are 
mapped in 2 regions of the genome: BHRF1 (Bam HI 
fragment H rightward open reading frame I) and BART 
(Bam HI-A region rightward transcript) [13]. The BART 
region encodes the cluster 1 and clusters 2 EBV-miRNAs, 
whereas the BHRF1 region contains only 3 miRNAs 
[14]. EBV-encoded miRNAs are differentially expressed 
among the different latency programs, being the latency 
III restricted to BHRF1 miRNA expression and the latency 
I and II to BART miRNA expression [15].
Since the role of EBV in BL pathobiology is still 
quite debated, and little is known about the influence of 
EBV-encoded miRNAs in primary BLs, we investigated 
the miRNA expression profiling of EBV-positive and 
EBV-negative BL, aiming at identifying differential 
miRNA patterns according to EBV infection status and at 
determining the contribution of EBV-derived miRNAs to 
BL molecular profile.
RESULTS
Burkitt lymphomas differ for gene expression 
and cellular pathway regulation according to 
EBV presence
First, we aimed to assess whether BL cases 
differed in gene expression according to the EBV status. 
Unsupervised approaches confirmed that BL is a rather 
homogenous disease. In fact, both principal component 
analysis (PCA) and unsupervised hierarchical clustering 
(HC) failed to discriminate cases according to either the 
clinical type (endemic versus sporadic versus HIV) and 
the EBV status (positive versus negative) (Figure 1A–1B).
However, when supervised analysis was performed 
(T-test, p < 0.05, fold change ≥ 2, Benjamini Hockeberg 
FDR), we could clearly separate EBV-positive and 
EBV-negative BL based on the expression of 467 genes, 
differentially regulated in the two subsets. Specifically, 
355 genes were up-regulated in EBV-positive cases, 
while 112 genes were down-regulated (Figure 1C–1D; 
Supplementary Table 1).
To test its validity, this signature was further applied 
to an independent data set of cases that we previously 
studied with a different technology (accordingly, the 467 
genes corresponded to 858 probe sets in this analysis) 
[5] and, also in this set of cases, it efficiently separated 
the EBV-positive and EBV-negative groups (Figure 2A). 
Similarly, by applying a classification method based on a 
support vector machine algorithm, 33/34 samples (overall 
accuracy, 97%) were correctly classified (Supplementary 
Table 2).
Interestingly, among the most strongly upregulated 
genes in EBV-positive cases we found LIN28B, which 
is frequently over-expressed in diverse primary tumors, 
facilitating cellular transformation. Remarkably, LIN28B 
was recently found to serve as key driver gene in HBV-
induced carcinogenesis [36]. Further, we found CGNL1 
which encodes for a protein regulating the activity of 
the small GTPases RHOA and RAC1. Of note, RHOA 
malfunction due to somatic mutations has been recently 
described in BL [37, 38]. GCET2 (alias GCSAM or HGAL) 
was also found to be differentially expressed. This was 
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Figure 1: Unsupervised analyses (unsupervised hierarchical clustering, A. principal component analysis, B. failed to 
clearly discriminate Burkitt lymphoma (BL) subgroups based on the global gene profile. Supervised analysis (T-test) 
comparing EBV-positive and EBV-negative cases identified a series of differentially expressed genes C. In the matrix (A, C), 
the dendrogram was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, 
each column represents a sample and each row represents a gene. The color scale bar shows the relative gene expression 
changes normalized by the standard deviation (0 is the mean expression level of a given gene). The differentially expressed 
genes corresponded to significantly enriched biological functions according to Gene Ontology D.
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quite interesting. In fact, this gene encodes a protein which 
may function in signal transduction pathways and whose 
expression is usually elevated in germinal cell lymphomas 
and that regulates the RHOA signaling pathway [39].
SXX1 was also strongly over-expressed in EBV-
positive cases; this gene is commonly translocated 
in synovial sarcomas and renal adenocarcinoma with 
possible transforming activity [40]. Other genes with 
potential pathogenetic role include MRAS, PLCD4, 
SEL1L, the apoptosis regulators CIDEB and CRLF3, 
the methyltransferase METTL6 and the serine/threonine 
kinase encoding STK10/STK33.
The differential expression of the protein encoded 
by one of the genes included in the signature, GCET2, was 
validated at protein level by immunohistochemistry, which 
turned out to be positive in 5/7 EBV-positive versus 2/31 
EBV-negative cases (p = 0.0008) (Figure 2B).
Further, to make our data more robust, the differential 
expression of PLCD4, METTL6, CIDEB and CRLF3 was 
tested and validated in an independent, previously described 
set of cases, including 13 EBV-positive BL and 20 EBV-
negative BL cases [5](Supplementary Figure 1).
We then investigated whether the signature 
discriminating EBV-positive and EBV-negative BL 
cases was enriched for genes involved in specific cellular 
programs and functions and found that EBV-positive cases 
presented a significant de-regulation of genes related with 
apoptosis induction, this being in line with the known effects 
of the virus on B-cells. Most importantly, other programs 
with potential pathogenetic significance were enriched in 
EBV-positive BL, including some that are also mediated by 
known oncogenes such as KRAS, ALK, CCND1, and JNK, 
and programs related with signal transduction of G protein-
coupled receptors (GPCR) (Supplementary Table 3).
We subsequently investigated whether the 
classification of BL subtypes according to the EBV 
status was more robust than the clinical classification at 
the molecular level. To this aim, the molecular signature 
discriminating sBL and eBL, which we previously 
identified [5], was applied. According to this signature 
we could correctly classify all the cases (100% accuracy) 
as eBL or sBL, independently from the EBV status 
(Table 1), this indicating that BL arising in different 
settings, display significant molecular differences that are 
Figure 2: Validation of gene expression profiling. A. The molecular signature identified as distinctive of EBV-positive versus 
EBV-negative BL was applied to an independent set of cases, allowing a proper distinction of the two groups. In the matrix, each column 
represents a sample and each row represents a gene. The color scale bar shows the relative gene expression changes normalized by the 
standard deviation (0 is the mean expression level of a given gene). Immunohistochemical validation of mRNA results confirmed the 
differential expression of GCET, showing intense positivity in EBV-negative cases B. and negativity in EBV-positive cases C. which turned 
out to be strongly meaningful (p = 0.0008). As control for immunohistochemistry, a reactive germinal center was used D.
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not recapitulated by the EBV status. Most importantly, 
this finding demonstrated the actual value of the current 
clinical classification of BL subtypes. Of note, only 9/467 
genes differentially expressed between EBV-positive BL 
and EBV-negative BL overlapped with those differentially 
expressed between eBL and sBL (Supplementary Figure 2).
Burkitt lymphomas differ for viral miRNA 
expression according to EBV presence
Since significant differences were found in the 
transcriptional profile of BL according to EBV status, we 
investigated whether miRNA profiles could contribute to 
this diversity.
Similarly to what we observed through analysis of 
mRNA profiles, by using unsupervised approaches (PCA 
and HC) to miRNA profiles, we found that all BL subtypes 
were quite homogeneous, not being clearly discriminated 
into subgroups (Figure 3A–3B).
When a supervised analysis was adopted to identify 
specific miRNAs differentially expressed according to 
the EBV status (positive versus negative) of BL cases, we 
uncovered that one single cellular miRNA, namely hsa-
miR-659, differentiated the two groups, while 21 EBV-
encoded miRNAs were differentially expressed in the 
two categories (Figure 3C; Table 2). Of note, one sample, 
which was initially classified as EBV-negative, clustered 
within EBV-positive cases (Figure 3C, arrow) as it did 
at GEP analysis (Figure 1C, arrow). As this case showed 
expression of viral miRNAs, EBER analysis was repeated 
and eventually confirmed the EBV presence, though in 
a small minority of cells. Although anecdotal, this case 
underscored the reliability of the molecular mRNA and 
miRNA profiles in discriminating BL cases according to 
the EBV status.
We then investigated whether the differential viral 
miRNA signature of EBV-positive BLs was associated 
either with neoplastic lymphoid transformation or with 
the type-I viral latency program. To this end, viral 
miRNA signature was assessed in EBV-positive BL 
(EBV latency type I), EBV-positive PTLD (latency 
type III) and benign EBV-positive lymphadenopathy 
Table 1: Classification of BL cases according to the molecular signature discriminating eBL 
and sBL
Identifier BL subtype Predicted BL subtype Confidence Measure EBV status
BL_20 Endemic Endemic 0.9998895 NEG
BL_14 Endemic Endemic 1 POS
BL_15 Endemic Endemic 0.999925 POS
BL_17 Endemic Endemic 0.9999268 POS
BL_16 Endemic Endemic 0.99990785 POS
BL_18 Endemic Endemic 0.999925 POS
BL_19 Endemic Endemic 0.999931 POS
BL_21 Endemic Endemic 0.9999988 POS
BL_7 Sporadic Sporadic 0.99992514 NEG
BL_3 Sporadic Sporadic 0.9998459 NEG
BL_8 Sporadic Sporadic 0.99990106 NEG
BL_4 Sporadic Sporadic 0.99993503 NEG
BL_12 Sporadic Sporadic 0.9998819 NEG
BL_2 Sporadic Sporadic 0.9998722 NEG
BL_10 Sporadic Sporadic 0.9999405 NEG
BL_1 Sporadic Sporadic 0.99991775 NEG
BL_6 Sporadic Sporadic 0.9998288 POS
BL_5 Sporadic Sporadic 0.999936 POS
BL_11 Sporadic Sporadic 0.9998968 POS
BL_9 Sporadic Sporadic 0.99990225 POS
BL_13 Sporadic Sporadic 1 POS
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Figure 3: Unsupervised analyses (unsupervised hierarchical clustering, A. principal component analysis, B. failed to 
clearly discriminate Burkitt lymphoma (BL) subgroups based on the global miRNA profile. Supervised analysis (T-test) 
comparing EBV-positive and EBV-negative cases identified a series of differentially expressed miRNAs C. The hierarchical 
clustering of EBV-positive BL, benign lymphadenopathy and post-transplant lymphoproliferative disease (PTLD) indicated 
differences in regulation of the expression of viral miRNAs in the 3 settings D. In the matrix (A, B, C, D), the dendrogram 
was generated using a hierarchical clustering algorithm based on the average-linkage method. In the matrix, each column 
represents a sample and each row represents a miRNA. The color scale bar shows the relative gene expression changes 
normalized by the standard deviation (0 is the mean expression level of a given miRNA).
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(latency type I). Interestingly, we found that the viral 
miRNA profile of EBV-positive BL was not related with 
malignant lymphoid transformation, being different 
between EBV-positive BL and EBV-positive PTLD. 
Similarly, it was not related with a specific latency 
type, being differentially represented in EBV-positive 
BL and EBV-positive benign lymphadenopathy, both 
sharing a type-I latency program (Figure 3D). In 
particular, when EBV-positive BL and EBV-positive 
PTLD were compared, 10 viral miRNA turned out to 
be differentially expressed (Figure 4A; Supplementary 
Table 4), while 3 miRNA differentiated EBV-positive 
BL and EBV-positive benign lymphadenitis (Figure 4B; 
Supplementary Table 5). In both instances, viral-miRNAs 
were up-regulated in BL cases. These results supported 
the hypothesis that the expression pattern of EBV-related 
miRNAs in BL is disease-specific and suggested that 
in BL EBV-encoded miRNA might play a particularly 
significant role.
Virus-encoded miRNAs contribute to  
EBV-positive BL molecular profile
Following the demonstration of a specific EBV-
derived miRNA signature characterizing EBV-positive BLs, 
we investigated whether such EBV-related miRNAs exerted 
an actual influence over the transcriptional profile of BLs.
To investigate the possible roles of such miRNAs, 
we then explored their ability to affect GEP of the 
tumors. First, we retrieved the list of all EBV-encoded 
miRNA target genes biochemically proved so far 
(http://crdd.osdd.net/servers/virmirna/). From this list, 
we extracted the genes targeted by viral miRNA over-
expressed in EBV-positive BL. One hundred three of 
them were indeed differentially expressed in EBV-
positive versus EBV-negative BL. (Figure 5A–5B, 
Supplementary Table 6). This evidence was also confirmed 
in an independent series of cases for which GEP had been 
previously generated by our group (data not shown) (5).
Table 2: MicroRNAs differentially expressed between EBVpos and EBVng BL biopsies, as judged 
by miRNA profiling
miRNA p Value Fold change Regulation in EBV-negative BL
hsa-miR-659 5.216587E-4 3.1564796 down
ebv-miR-BART1–3p 2.2763237E-7 13.949068 down
ebv-miR-BART3 2.2763237E-7 25.136276 down
ebv-miR-BART4 2.2763237E-7 11.487968 down
ebv-miR-BART6–3p 8.566455E-7 9.675229 down
ebv-miR-BART6–5p 3.7144142E-7 8.102603 down
ebv-miR-BART7 1.8088365E-6 7.2138195 down
ebv-miR-BART8 2.2763237E-7 13.425398 down
ebv-miR-BART9 3.3071314E-7 19.268543 down
ebv-miR-BART10 4.381665E-6 7.4831443 down
ebv-miR-BART11–5p 2.2763237E-7 14.604774 down
ebv-miR-BART12 2.2763237E-7 9.735685 down
ebv-miR-BART13 7.181049E-4 2.6553512 down
ebv-miR-BART15 2.0135598E-5 4.21289 down
ebv-miR-BART17–3p 2.2763237E-7 19.245274 down
ebv-miR-BART17–5p 6.5513194E-7 7.0488086 down
ebv-miR-BART18–3p 5.83144E-4 2.412564 down
ebv-miR-BART18–5p 2.3061666E-6 5.701385 down
ebv-miR-BART19–3p 3.7144142E-7 11.179877 down
ebv-miR-BART19–5p 3.7144142E-7 12.813777 down
ebv-miR-BART21–3p 1.1779003E-7 15.055322 down
ebv-miR-BART22 1.1779003E-7 54.28091 down
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Interestingly, at GSEA the differentially expressed 
miRNA targets tuned out to be significantly involved 
in regulation of transcription and gene expression, 
nucleotide/RNA metabolism, and most often apoptosis. 
Moreover, they could be related to some pathways often 
involved in tumorigenesis such as those controlled by 
TP53, TGFB, CCND1, TBK1, LTE2, MTOR, STK33, and 
HOXA9 (Figure 5C–5D; Supplementary Table 7).
Among others, we noted – for the potential 
pathobiological significance, the differential expression 
of BAX, involved in apoptosis regulation; JAG1, the 
physiological ligand of NOTCH1; KLHL18, a ligase 
that regulates mitotic entry and ubiquitylates Aurora-A; 
and NCK1, one of the signaling and transforming 
proteins containing Src homology 2 and 3 (SH2 and 
SH3) domains involved in transducing signals from 
receptor tyrosine kinases to downstream signal recipients 
such as RAS (Figure 6).
In addition, an ad hoc functional experiment 
was performed to investigate the specific effects of the 
prototypical EBV-derived miRNA BART6–3p. The Akata 
cell line with the BART6–3p inhibitor, and the effects on 
such inhibition on the global transcriptome were analyzed. 
We found that BART6–3p knocking-down (verified by 
q-PCR, Figure 7A), led to the modified expression of a 
set of genes, which included 86 induced probes and 76 
repressed probes, corresponding to 36 and 57 unique 
genes, respectively (Figure 7B, Supplementary Table 8).
Noteworthy, GSEA consistently demonstrated the 
differential expression of the genes previously demonstrated 
to be targeted by BART6–3p according to viRmiRNA and 
those identified by us (Supplementary Table 8), between the 
transfected Akata cells and the primary EBV-positive and 
EBV-negative subsets (Figure 7C–7E) respectively, further 
supporting the direct role of EBV-encoded miRNAs in the 
modulation of BL gene expression profile.
Figure 4: Supervised analysis (Mann-Whitney, p-value < 0.05; fold change >2) confirmed differences between  
EBV-positive BL and EBV-negative positive PTLD A. and EBV-positive lymphadenitis B. in terms of EBV-encoded 
miRNA. In the matrix (A, B), the dendrogram was generated using a hierarchical clustering algorithm based on the 
average-linkage method. In the matrix, each column represents a sample and each row represents a miRNA. The color scale 
bar shows the relative gene expression changes normalized by the standard deviation (0 is the mean expression level of a 
given miRNA).
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Figure 5: EBV-encoded miRNA significantly impact on BL gene expression profile. A. Among the 2,624 genes so far 
demonstrated at biochemical level to be targeted by EBV-encoded miRNAs, 1, 935 are targeted by miRNAs over-expressed in EBV-
positive BL. Among these, we found 103 to be differentially expressed between EBV-positive and EBV-negative BL cases. B. Based on the 
expression of such 103 genes, EBV-positive and EBV-negative BL cases were clustered. These 103 genes were involved in oncopathways 
mastered by known oncogenes C. and biological processes related to the regulation of apoptosis, transcription and nucleic acid metabolism D.
Figure 6: The expression levels of BAX, JAG1, KLH18, and NCK1 in Burkitt lymphoma according to EBV presence. Box 
plot correspond to normalized gene expression values; bars indicate median values as well as 95% confidence intervals. Two tails unequal 
Student T-test was used for comparisons.
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DISCUSSION
Since its identification as tumor-associated virus 
in Burkitt lymphoma, EBV has been implicated in the 
development of a wide range of lymphoproliferative 
disorders, also including Hodgkin lymphoma and post-
transplant lymphoproliferative disease [41, 42]. However, 
the exact mechanism of action of EBV in human cancer, 
and especially in BL, is still debated [43–45]. Although 
the number of the products encoded by EBV in its latent 
states is very limited, during its evolution the virus has 
gained the capability of interfering with different cellular 
physiologic mechanisms which could explain the virus’s 
contribution to hman malignancies. [4, 12, 46–50]. The 
abovementioned EBV-encoded products include 9 latent 
proteins, two RNA molecules without known coding 
properties (i.e. EBERs) and at least 40 miRNA molecules, 
most of which belong to BART family. Furthermore, these 
molecules are not expressed equally in different conditions 
where the virus occurs to be present, and different viral 
latency types are defined on the basis of the expression 
pattern of the latent proteins [9, 51–53].
The lack of the expression of the viral oncoproteins 
like LMP-1 in BL has cast doubt about the role of EBV in 
BL. In fact, BL shows the latency type I of EBV, where 
the only viral latent protein expressed EBNA-1 [12, 54]. 
However, there are several documents, both in vitro and 
in vivo, which support such a role. One classical example 
to be mentioned is the study performed by De-The et al. 
in 1978 in Uganda: the children who later developed BL 
Figure 7: A. Transfection efficiency of AKATA cell lines with BART6 inhibitor was confirmed by quantitative  
RT-PCR. B. Gene expression profiles were generated in AKATA cell lines transfected with BART6 inhibitors and negative 
controls. Supervised analysis of the two groups revealed differential expression of 93 unique genes. C. The expression of BART6 
targets previously validated at biochemical level was tested upon transfection. Indeed, we found a highly significant enrichment that 
confirmed the accuracy of the tool. D–E. Gene set enrichment analysis documented as the genes differentially expressed in AKATA 
cell line upon BART6 inhibition were significantly enriched in primary cases supporting the functional role of BART6 in vivo.
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showed a higher titer of antibodies against EBV [55]. In 
addition, results of a study of deep sequencing of primary 
BL cases showed higher mutation rates in EBV-negative 
cases, indicating a possible substituting role of EBV for 
those mutations [56, 57]. Accordingly, Vereide et al. showed 
that although the infected cells might lose the virus by 
chance, the infected malignant cells seem to depend upon 
the virus, as they maintain it for apoptosis inhibition [58]. 
In all, although EBV does not appear to be able to induce 
BL malignant phenotype by itself as oncogenic activation 
(typically MYC translocation and over-expression) is anyway 
necessary, EBV is currently considered to facilitate B cell 
transformation in BL tumorigenesis by inducing a clonal 
expansion of an apoptosis resistant population [59, 60].
As EBV may contribute to BL pathogenesis with 
both genes and miRNA, in this study we performed an 
extensive gene and miRNA expression profile of BL cases 
carrying or not EBV aiming to evaluate for the first time 
the influence of virus-encoded miRNA on the global 
molecular profile of the tumor.
We first proved, for the first time, that BL can be 
differentiated by gene expression profiling based on the 
presence of EBV. This is not trivial, as it indicates that 
the presence of EBV determines significant effects on 
the cellular programs of the transformed B-cell that are 
maintained even when the full lymphomatous phenotype 
is acquired.In this regard, it should be noted that genes 
differentiating EBV-positive and EBV-negative BL are 
significantly involved in apoptosis regulation, confirming 
that cell death impairment might be at least in part 
mediated by the virus in BL cells. Previous GEP studies 
actually indicated that BL subtypes have a largely common 
profile, different from the ones of other lymphomas and 
that eBL, sBL, and ID-BL can be distinguished based on 
the gene expression signature [5, 16, 25, 61].
In this regard, intriguingly, when we tried to 
understand whether the distinction of BL according to the 
EBV status was more robust than the clinical categorization, 
this implying a possible new classification system, we found 
that the clinical setting maintained a significant impact. In 
fact, by applying a previously identified molecular signature 
able to discriminate eBL and sBL [5], we could correctly 
classify all the cases independently from the EBV status. 
This proved that BL arising in different settings, beside EBV 
status, have significant molecular differences and confirmed 
the value of the current classification. Consistently, only few 
genes were in common between the two signatures.
The evidence of significant differences in EBV-positive 
and EBV-negative cases at GEP, prompted us to investigate 
whether viral miRNA could contribute to this phenomenon 
as miRNA and global gene expression have never been 
integrated in this setting. We found significant differences in 
the miRNA profile of tumors carrying or not EBV. However, 
consistent with a previous report [6], we failed to identify 
significant differences concerning cellular miRNA, while 
viral miRNA designated the different patterns. Of interest, 
only a subset of viral miRNA turned out to be expressed 
in EBV-positive cases, largely corresponding to the BART 
family. By contrast, no miRNA from the BHRF regions were 
expressed. This observation was consistent with the latency 
I program typical of BL, and appeared to confirm confirming 
previous reports on EBV-encoded miRNA expression in 
EBV-associated tumors [62]. However, to further dissect this 
issue, we evaluated the expression pattern of viral miRNA 
in cases of non malignant EBV-positive lymphadenitis, 
characterized by the same latency I program as well as in 
PTLD, an EBV-positive lymphoid malignancy characterized 
by a latency III program. We could identify clear differences 
between BL and PTLD, which also expressed molecules 
belonging to the BHRF family. However, surprisingly, we 
found significant differences between BL and non neoplastic 
samples as well, this indicating for the first time that the 
EBV-encoded miRNA expression pattern is not univocally 
dependent on the latency type.
In the last years, an increasing number of publications 
have stressed the role of EBV-encoded miRNAs in the patho-
biology EBV-related tumors, with anti-apoptotic properties as 
the major indication [11, 63–65]. Very interestingly, it seems 
that BL cells totally depend upon BART miRNAs in order 
to exhibit their tumor-related properties [58]. In this regard, 
we showed that  BART6-3p, an EBV-encoded miRNA, may 
exert growth-inducing properties and affect immune response 
and impact the global gene expression profile of EBV-
positive BL, when compared to EBV-positive PTLD [11, 54]. 
Here, as a proof of principle, we demonstrated that BART6-
3p might affect the gene expression profile of EBV-positive 
BL at global level, when compared to EBV-negative BL. 
A similar effect for other BART miRNAs could be assumed, 
as demonstrated by us in the case of EBV-positive ID-BL 
[66], however it must be noted that the miRNA-miRNA 
interactions might be needed to be interpreted in a complex 
network in which the outcome of the co-expression of several 
miRNAs be different from simple sum of their effects, due to 
possible synergism/antagonism among them [67].
In conclusion, our study provided for the first time 
evidences that EBV-positive and EBV-negative BL have a 
distinct GEP and that EBV-encoded miRNAs significantly 
affect BL molecular phenotype by opening new scenarios 
in the study of BL and other lymphomas and more 
generally of EBV-related diseases.
MATERIALS AND METHODS
Case collection
We collected 30 BL cases from different Italian and 
African institutions, including 8 endemic, 13 sporadic 
and 9 immunodeficiency-related BLs, corresponding to 
13 EBV-positive and 17 EBV-negative cases. Furthermore, 
5 EBV-positive post-transplant lymphoproliferative disease 
(PTLD) and 2 EBV-positive benign lymphadenopathy 
cases were included as control (Table 3). The diagnosis 
was made by at least 3 expert hematopathologists and 
confirmed as previously described [5, 16].
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Table 3: Sample description for the tumor and normal biopsies used for miRNA profiling
Samples Disease Subtype EBER EBV latency
BL_001 BL Sporadic NEG NA
BL_002 BL Sporadic NEG NA
BL_003 BL Sporadic NEG NA
BL_004 BL Sporadic NEG NA
BL_007 BL Sporadic NEG NA
BL_008 BL Sporadic NEG NA
BL_010 BL Sporadic NEG NA
BL_012 BL Sporadic NEG NA
BL_020 BL Endemic NEG NA
BL_023 BL Immunodeficiency-related NEG NA
BL_024 BL Immunodeficiency-related NEG NA
BL_025 BL Immunodeficiency-related NEG NA
BL_030* BL Immunodeficiency-related NEG NA
BL_005 BL Sporadic POS Type I
BL_006 BL Sporadic POS Type I
BL_009 BL Sporadic POS Type I
BL_011 BL Sporadic POS Type I
BL_013 BL Sporadic POS Type I
BL_014 BL Endemic POS Type I
BL_015 BL Endemic POS Type I
BL_016 BL Endemic POS Type I
BL_017 BL Endemic POS Type I
BL_018 BL Endemic POS Type I
BL_019 BL Endemic POS Type I
BL_021 BL Endemic POS Type I
BL_022 BL Immunodeficiency-related POS Type I
BL_026 BL Immunodeficiency-related POS Type I
BL_027 BL Immunodeficiency-related POS Type I
BL_028 BL Immunodeficiency-related POS Type I
BL_029 BL Immunodeficiency-related POS Type I
(Continued )
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Gene expression profiling of primary Burkitt 
lymphomas
Gene expression profile analysis was carried on 
by using the DASL whole genome assay starting from 
formaldehyde-fixed, paraffin-embedded (FFPE) tissues 
[17–22]. RecoverAll™ Total Nucleic Acid Isolation Kit 
(Life Technologies, Monza, Italy) was used to extract total 
RNA from FFPE tissues. Up to five 10 μm sections were 
processed per reaction. FFPE samples were deparaffinized 
using a series of xylene and ethanol washes. Next, they 
were subjected to a rigorous protease digestion with an 
incubation time tailored for recovery of total RNA. RNA 
was purified using a rapid glass-fiber filter methodology 
that includes an on-filter DNase treatment and were eluted 
into the low salt buffer provided. RNA was quantified 
using NanoDrop spectrophotometer.
Further, total RNA was converted to cDNA using 
biotinylated oligo (dT) and random nonamer primers. The 
biotinylated cDNA was then annealed to the DASL Assay 
Pool (DAP) probe groups that contain oligonucleotides 
specifically designed to interrogate each target sequence 
in the transcripts. As these probes span about 50 bases, it 
is possible to profile partially degraded RNA. Following 
this, correctly annealed, assay-specific, oligos were 
extended and ligated to generate amplifiable products. 
These templates were labeled during PCR amplification by 
including fluorescent primers in the reaction. The resulting 
PCR products were scanned using the BeadArray Reader 
or iScan System to determine the presence or absence of 
specific genes.
Gene expression analysis was carried on as 
previously reported [5, 23–25]. Unsupervised clustering 
was generated using a hierarchical algorithm based 
on the average-linkage method [26, 27]. Only genes 
displaying a twofold average change in the expression 
level across the whole panel were chosen to generate 
the hierarchical clustering. The expression value of each 
selected gene is normalized to have a zero mean value 
and unit standard deviation. The distance between two 
individual samples was calculated by Pearson correlation 
with the normalized expression values. To perform the 
supervised gene expression analysis, we used GeneSpring 
GX 12 (Agilent, MI, Italy) [5]. Differentially expressed 
genes between different groups were identified using a 
two-tails Student t-test and adjusted Benjamini-Hochberg 
correction for false discovery rate, applying the following 
filtering criteria: p-value <0.05, and fold change >2. 
A Support Vector Machine algorithm was used for sample 
classification as previously reported [5, 28].
EASE software was applied in order to establish 
whether specific cell functions and biological processes, 
defined according to gene ontology [29, 30], were 
significantly represented among the deregulated genes 
[31, 32].
Gene set enrichment was calculated with the use of 
Gene Set Enrichment Analysis (GSEA) [33] with t test–
based P values for weighting statistics.
Gene expression analysis was carried on according 
to MIAME guidelines. Raw gene expression data will be 
available at http://www.ncbi.nlm.nih.gov/projects/geo/ 
after publication (GSE63665).
miRNA profiling of primary Burkitt lymphomas
MicroRNA expression profiling was performed 
using Nanostring nCounter® miRNA Expression Assay 
Kits (Human V1 miRNA NanoString Technologies, 
Seattle, WA, USA)… Raw data coming from nCounter® 
miRNA Expression Assay were normalized using 
NanoStringNorm package developed in R 2.15 version. 
Briefly, probe levels quantified by microarrays were 
adjusted for miRNAs with specific background correction 
factor. Technical normalization was performed using 
geometric mean of positive controls and mean of negative 
controls for background subtraction. Lastly, the dataset 
was normalized such that the mean of each gene is zero. 
The data were further analyzed using GeneSpring GX12. 
The miRNAs differentially expressed between the two 
categories were selected on the basis of the following 
criteria: fold change ≥ 2, corrected p-value (Benjamini-
Hockeberg FDR) ≤ 0.05 [34].
Samples Disease Subtype EBER EBV latency
PTLD_031 PTLD DLBCL POS Type III
PTLD_032 PTLD DLBCL POS Type III
PTLD_033 PTLD DLBCL POS Type III
PTLD_034 PTLD DLBCL POS Type III
PTLD_035 PTLD DLBCL POS Type III
MNC_036 Lymphadenopathy Lymphadenopathy POS Type I
MNC_037 Lymphadenopathy Lymphadenopathy POS Type I
*Not used in miRNA profiling.
NA: not available
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As a source for experimentally validated 
EBV-encoded miRNA targets, we used viRmiRNA 
(http://crdd.osdd.net/servers/virmirna/), a recently 
established database which in addition covers Experimental 
viral miRNAs and Experimental antiviral miRNAs of a 
wide range of human and non-human viruses [35].
Cell transfection and gene expression analysis
For functional validation experiments, the 
EBV-positive BL Akata cell line was transfected 
with BART6–3p inhibitor or a negative control of 
inhibitor (NCI, Dharmacon- Thermo Scientific, Germany) 
using Amxa Nucleofector apparatus (Amaxa, Cologne-
Germany), program G23 and transfection solution V, 
according to the manufacturer’s instructions. RNA was 
extracted 24 hours post-transfection, and the transfection 
efficiency was confirmed by q-PCR by means of Taqman 
probes (Applied Biosystems, Germany), employing 
RNU43 as housekeeping miRNA, as described previously 
[12]. The expression levels were calculated by ΔΔCT 
method utilizing NCI sample as control. RNA was further 
processed according to the manufacturer’s instructions 
and hybridized on the HuGene-2.0-st array (Affymetrix, 
Santa Clara, CA). HuGene-2.0-st CEL files were 
quantile normalized and log2 transformed using rma 
method implemented by the Bioconductor R package for 
Affymetrix as previously reported [5, 23–25]. Supervised 
analysis (two-tails student T-test) was performed to 
obtain molecular signatures of different cell lines using 
geWorkbench 2.4.1 software and filtered using the 
following criteria: p-value < 0.01, fold change ≥ 3.
Enrichment in expression of BART6–3p predicted 
and experimentally found targets was evaluated using 
GSEA software on a set of 12 EBV-positive endemic, 
2 immunodeficiency-related and 21 sporadic BL samples 
which were extracted from GEO database and normalized 
as described above [5].
The study was conducted according to the principles 
of the Helsinki declaration after approval of the Internal 
review Board.
Immunohistochemistry
GCET2 immunohistochemical staining was 
performed as follows: 2–4-μm-thick paraffin-embedded 
tissues were cut onto Dako slides (DAKO), and 
subsequently dewaxed, rehydrated and subjected 
to antigen retrieval by heating in 50 mM Tris 
(tris(hydroxymethyl)aminomethane) (Trizma base)-
2 mM EDTA (ethylenediaminetetraacetic acid) (Sigma 
Chemical, St Louis, MO) (pH 9) in a microwave pressure 
cooker (A Menarini Diagnostics, Wokingham, UK) at 
900 W for 2 minutes. The slides were cooled and treated 
with peroxidase-blocking solution (DAKO) for 5 minutes. 
Sections were then immunostained with Gcet1 mAb by the 
two-stage peroxidase-based EnVision technique (DAKO), 
counterstained with hematoxylin and mounted.
Incubations containing unrelated antibodies were 
used as a control of the technique. The difference of the 
expression level between the cases was evaluated using 
two-tailed Fisher’s exact test
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